Ability Biologics Secures $18M in Seed Funding for Expansion and R&D

Ability Biologics raises $18M in Seed Funding

Ability Biologics (Linkedin), a Montreal-based cell targeting company, has secured $18M in seed funding to advance their innovative antibody therapeutics. They are seeking partnerships with biotech and pharmaceutical companies to address significant unmet medical needs.

Funding Amount: $18 million

Industry: Biotechnology Research

Employee Count: 2-10

CEO: Giles Day (CEO Linkedin)

What Ability Biologics needs to buy: Ability Biologics is looking for partners in the biotech and pharmaceutical industries who can provide research and laboratory equipment, collaborate on joint R&D; projects, and offer manufacturing and supply chain solutions for efficient production and distribution of their antibody therapeutics. Companies specializing in cell targeting technologies and antibody development are ideal partners for Ability Biologics.